Italia markets open in 50 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
21,19-0,08 (-0,38%)
Alla chiusura: 04:00PM EDT
21,13 -0,06 (-0,28%)
Dopo ore: 07:57PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

    CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.Leak of CUNY report preceded by massive increase in short selling. AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzh

  • GlobeNewswire

    Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

    CEO to Present on Wednesday, October 11th, at 10:30am ETAUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available. Live Webcast: https

  • GlobeNewswire

    Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease

    804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer’s patients are enrolled in this 12-month trial.